Naltrexone Treatment Centers in New Hampshire

No. New Hampshire MAT providers do not require criminal-history disclosure to enroll. Federal law (42 CFR Part 2) protects substance-use treatment records; a criminal record will not block admission to a naltrexone program.

Cash-pay monthly cost for Sublocade in New Hampshire typically runs $1,400–$1,900 per injection, plus administration fees. Manufacturer savings programs, 340B pricing at FQHCs, and State Opioid Response grants can significantly reduce this out-of-pocket cost.

Yes. Pregnancy-related New Hampshire Medicaid (Granite Advantage) coverage includes MAT with no copays and priority access to New Hampshire perinatal-MAT programs. Many New Hampshire Medicaid (Granite Advantage) plans also extend coverage for 12 months postpartum to protect the mother–infant dyad.

Yes. TRICARE Prime and Select cover the full MAT benefit including naltrexone. Active-duty service members may need command notification; retirees and dependents do not. Humana Military or Health Net Federal handles TRICARE claims depending on the New Hampshire region.

Yes. naltrexone is a federally approved medication used legally across New Hampshire. Methadone is dispensed only at SAMHSA-certified Opioid Treatment Programs (OTPs); buprenorphine is prescribed by licensed clinicians; naltrexone has no prescriber waiver requirement. State licensing agencies oversee all naltrexone providers.

No. There is no legal or clinical cap on how long you can remain on naltrexone in New Hampshire. Insurance must continue to cover MAT as long as the prescribing clinician documents medical necessity.

No. New Hampshire employers have no right to require MAT disclosure. ADA protections and 42 CFR Part 2 confidentiality prevent providers from disclosing MAT status to employers. If you need FMLA for appointments, your HR can verify medical leave without knowing the diagnosis.

Yes. Basic labs include a urine drug screen, pregnancy test (if applicable), hepatitis and HIV testing (offered, not mandatory), liver-function tests, and for methadone an ECG to screen QTc interval. Labs are usually drawn at intake; results guide medication selection.

During induction (first 1–2 weeks), mild drowsiness is common. Once stabilized, most patients fully resume work, including safety-sensitive jobs such as CDL driving, subject to any employer drug-testing policies. New Hampshire clinicians can issue letters documenting stability.

Neonatal Opioid Withdrawal Syndrome (NOWS) can occur in infants exposed to methadone or buprenorphine prenatally and is routinely monitored at New Hampshire delivery hospitals. NOWS is manageable with skilled nursing care; most infants go home within days to weeks with normal outcomes.

Patients prescribed buprenorphine or naltrexone in New Hampshire can technically receive medication without counseling, but outcomes are significantly better with integrated counseling. Methadone patients at OTPs have counseling requirements per federal rule 42 CFR Part 8.

Under the ADA, you cannot be fired solely because you are enrolled in naltrexone. Current illegal drug use is not protected, but lawful MAT enrollment is. Safety-sensitive roles (CDL, aviation) have additional rules — an employment attorney can review your specific situation.